XXXX : treatment outcomes with topical @entity801 in addition to systemic antibiotics.

@entity1 @entity801 @entity2782 @entity3637 @entity2177 @entity281 @entity23782 @entity393 @entity5505 @entity298
BACKGROUND: Although, @entity2782 ( @entity281 ) is recognized as a major complication of @entity298 ( @entity298 ) with high risk of @entity393 due to refractory/recurrent @entity298 , there is remarkably little literature about treatment outcomes. International Society for Peritoneal Dialysis guidelines advise the use of one to two antibiotics; in addition, we change standard exit-site care by stopping prophylactic @entity23782 and starting regular use of @entity801 1% cream. METHODS: Retrospective review of outcomes of Pseudomonas @entity281 from January 2012 to March 2015. RESULTS: During the study period, a total of 135 @entity1 were on @entity298 with an overall incidence of any @entity281 of 0.36/ @entity1 -year. There were 14 @entity1 with @entity281 episodes with Pseudomonas with a rate of 0.12/ @entity1 -year. In total, 13 of 14 @entity1 with @entity281 episodes were treated with oral @entity2177 and/or intraperitoneal (IP) @entity801 or @entity5505 , plus topical @entity801 , with a success rate of 38% (5/13). One @entity1 had @entity801 -resistant Pseudomonas species and was treated successfully with topical polymyxin/ @entity3637 cream. Median follow-up time in cured @entity1 was 385 days (range 74-1107). Six @entity1 had associated with @entity298 , four during follow-up and two at initial presentation. Three @entity1 had recurrent @entity281 with Pseudomonas, with one successfully re-treated with topical and IP @entity801 . In total, in only 50% of the @entity1 was Pseudomonas @entity281 successfully treated. Five of the @entity1 (36%) changed modality to permanent haemodialysis following catheter removal. CONCLUSION: Eradication of Pseudomonas @entity281 remains difficult even with the addition of topical @entity801 to the exit site. There should be a low threshold for catheter replacement.
